A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages

Journal of Lipid Research

Volumn 42, Issue 5, 2001, Pages 697-709

  Kobayashi, Kazuko ^a   Matsuura, Eiji ^a   Liu, Qingping ^a   Furukawa, Jun Ichi ^b   Kaihara, Keiko ^a   Inagaki, Junko ^a   Atsumi, Tatsuya ^c   Sakairi, Nobuo ^b   Yasuda, Tatsuji ^a   Voelker, Dennis R ^d   Koike, Takao ^c  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Antiphospholipid syndrome; Autoantibody; Cholesteryl ester; Macrophage

Indexed keywords

7 KETOCHOLESTERYL 9 CARBOXYNONANOATE; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CHOLESTEROL ESTER; LIGAND; LIPOSOME; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; ATHEROGENESIS; CHEMICAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIGAND BINDING; MACROPHAGE; MASS SPECTROMETRY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; ARTERIOSCLEROSIS; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CELL LINE; ENDOCYTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HUMANS; LIGANDS; LIPOPROTEINS, LDL; LIPOSOMES; MACROPHAGES; MAGNETIC RESONANCE SPECTROSCOPY; METHYLATION; MICE; MOLECULAR STRUCTURE; PHOSPHOLIPIDS; THROMBOSIS;

EID: 0034990570     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Thrombosis in systemic lupus erythematosus: Striking association with the presence of circulation lupus anticoagulant
2. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
3. The anticardiolipin syndrome
4. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
5. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
6. 2-glycoprotein I (apolipoprotein H)
7. 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus
8. The concept and classification of antiphospholipid/cofactor syndromes
9. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface
10. Amino acid sequence and location of the disulfide bonds in bovine beta 2 glycoprotein I: The presence of five Sushi domains
11. 2-glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles
12. Isolation of a specific lipid-binding protein from human serum by affinity chromatography using heparin-sepharose
13. 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects
14. 2-glycoprotein I-dependent manner
15. 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies
16. Adhesion mechanism of human beta (2)-glycoprotein I to phospholipids based on its crystal structure
17. 2-Glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway
18. 2-glycoprotein-I
19. 2-Glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation
20. 2-Glycoprotein-I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies
21. Pathogenesis of atherosclerosis - An update
22. The pathogenesis of atherosclerosis: A perspective for the 1990s
23. Low density lipoprotein undergoes oxidative modification in vivo
24. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man
25. Oxidized lipoproteins, altered cell function and atherosclerosis
26. Role of oxidized LDL and antioxidants in atherosclerosis
27. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus
28. 2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome
29. 2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein
30. 2-glycoprotein-I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages
31. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes on oxidized low-density lipoprotein
32. 2-glycoprotein 1 (and other proteins)
33. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipidprotein adducts inhibit macrophage uptake of oxidized low-density lipoproteins
34. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo
35. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor
36. 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome
37. Anticardiolipin antibodies in NZW x BXSB F1 mice: A model of antiphospholipid syndrome
38. 2-glycoprotein I as an anticardiolipin colfactor determined using deleted mutants expressed by a baculovirus system
39. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
40. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction
41. A simple method for the isolation and purification of total lipids from animal tissues
42. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages
43. 2-glycoprotein I: Reduction of antigenicity and the structural relationship
44. Low density lipoprotein oxidation and its pathobiological significance
45. Improved measurement of low-density lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein
46. Oxidative modification of LDL: Comparison between cell-mediated and copper-mediated modification
47. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides
48. Antiphospholipid antibodies and atherosclerosis
49. Autoxidation of human low density lipoprotein: Loss of polyunsaturated fatty acids and E and generation of aldehydes
50. 2-GPI mediated by the kringle IV domain
51. 2
52. A method for defining the stages of low-density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC
53. Cholesteryl hydroperoxyoctadecadienoate from oxidized low density lipoprotein inactivates platelet-derived growth factor
54. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque
55. Oxysterols and atherosclerosis
56. Identification of cholesterol-bound aldehydes in copper-oxidized low density lipoprotein
57. Lipid esterbound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins
58. Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions
59. Femtomole analysis of 9-oxononanoyl cholesterol by high performance liquid chromatography
60. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes; a possible mechanism of foam cell formation
61. The uptake of LDL-IC by human macrophages: Predominant involvement of the FcγRI receptor
62. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates
63. Immune complexes of LDL induce atherogenic responses in human monocytic cells
64. Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG Fc receptors
65. 2GPI
66. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis
67. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes
68. Lipoprotein oxidation and lipoprotein-induced cytotoxicity
69. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ